Myrtle Potter - Myovant Sciences Chairman of the Board
| MYOVDelisted Stock | USD 26.98 0.01 0.04% |
Chairman
Ms. Myrtle Stephens Potter is Chairman of the Board of the Company. She has served as Vant Operating Chair of Roivant Sciences, Inc., a whollyowned subsidiary of Myovants controlling shareholder, Roivant Sciences Ltd., since July 2018. In addition to serving on the Board, Ms. Potter is expected to serve on the board of directors of certain other subsidiaries of Roivant Sciences Ltd. Ms. Potter founded Myrtle Potter Company, LLC, a private healthcare and life sciences consulting firm, in September 2005, and served as the Chief Executive Officer until July 2018. From August 2009 until December 2014, Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to that, Ms. Potter held various positions, including President, CardiovascularMetabolics at BristolMyers Squibb and a vice president at Merck Co. Ms. Potter currently serves on the boards of directors of Rite Aid Corporationrationration, a leading drugstore chain, Liberty Mutual Holding Company Inc., a diversified global insurance company, Axsome Therapeutics, Inc., a biopharmaceutical company, INSMED Incorporated, a biopharmaceutical company, and a number of privately held companies. Ms. Potter previously served on the boards of directors of Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016, and Amazon.com, Inc., a leading ecommerce company, from 2004 to 2009. She also served on the boards of directors of Medco Health Solutions Inc. and Express Scripts Holding Co., subsequent to its acquisition of Medco Health Solutions, as well as other privately held companies since 2018.
| Age | 61 |
| Tenure | 6 years |
| Phone | 44 20 7400 3351 |
| Web | https://myovant.com |
Myovant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1822) % which means that it has lost $0.1822 on every $100 spent on assets. This is way below average. Myovant Sciences' management efficiency ratios could be used to measure how well Myovant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 358.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Myovant Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Myovant Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Myovant Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Myovant to invest in growth at high rates of return. When we think about Myovant Sciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 11 records | CHAIRMAN Age | ||
| David Farr | Emerson Electric | 64 | |
| Victor Coleman | Hudson Pacific Properties | 62 | |
| Harvey Blau | Griffon | 82 | |
| Anthony Best | Newpark Resources | 71 | |
| Harel Gadot | Microbot Medical | 51 | |
| Stephen Bershad | EMCOR Group | 74 | |
| Anthony Guzzi | EMCOR Group | 60 | |
| Alec Covington | Topbuild Corp | 64 | |
| Ronald Kramer | Griffon | 66 | |
| Fred Lampropoulos | Merit Medical Systems | 74 | |
| David Anderson | Newpark Resources | 74 | |
Management Performance
| Return On Asset | -0.18 |
Myovant Sciences Leadership Team
Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc. | ||
| Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc | ||
| Mark Altmeyer, Independent Director | ||
| Nancy Valente, Director | ||
| Kim Sablich, Chief Commercial Officer | ||
| Adele Gulfo, Director, Interim Chief Commercial Officer | ||
| Myrtle Potter, Chairman of the Board | ||
| Terrie Curran, Independent Director | ||
| Lauren Merendino, Chief Commercial Officer | ||
| Keith Manchester, Director | ||
| Marianne Romeo, Head, Global Transactions & Risk Management | ||
| Ann Tomlin, VP HR | ||
| Juan MD, Chief Officer | ||
| Uneek Mehra, Chief Financial and Business Officer, Principal Financial and Accounting Officer | ||
| Frank Torti, Director | ||
| Andria MD, Head Pharmacovigilance | ||
| Matthew JD, Gen Sec | ||
| Vivek Ramaswamy, Director | ||
| Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development | ||
| Albert Liao, Director Communications | ||
| Wayne DeVeydt, Independent Director | ||
| Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. | ||
| Kathleen Sebelius, Lead Independent Director | ||
| Mark Guinan, Independent Director | ||
| David Marek, Principal Executive Officer, Director | ||
| Hiroshi Nomura, Director | ||
| Bryan Selby, VP Devel | ||
| Lynn Seely, Principal Executive Officer, Director |
Myovant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.48) % | |||
| Operating Margin | (0.39) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 97.26 M | |||
| Shares Owned By Insiders | 48.61 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Number Of Shares Shorted | 8.39 M | |||
| Price To Earning | (8.56) X | |||
| Price To Book | 70.01 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Myovant Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Myovant Sciences' short interest history, or implied volatility extrapolated from Myovant Sciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Myovant Stock
If you are still planning to invest in Myovant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Myovant Sciences' history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |